Danirixin

DRUG6 trials

Sponsors

GlaxoSmithKline

Conditions

Infections, Respiratory Syncytial VirusPulmonary Disease, Chronic Obstructivechronic obstructive airways disease (COPD)

Phase 1

Evaluation of Danirixin (GSK1325756) Inhibition of CD11b Cell Surface Expression

CompletedNCT02201303

GlaxoSmithKlineInfections, Respiratory Syncytial Virus

Start: 2014-01-13End: 2015-07-02Updated: 2017-05-09

GSK1325756 Relative Bioavailability Study in Healthy Elderly Subjects

CompletedNCT03457727

GlaxoSmithKlinePulmonary Disease, Chronic Obstructive

Start: 2018-03-07End: 2018-07-25Updated: 2021-05-19

Phase 2

Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations

CompletedNCT02130193

GlaxoSmithKlinePulmonary Disease, Chronic Obstructive

Start: 2014-02-13End: 2016-08-29Updated: 2017-07-02

Danirixin Dose Ranging Study in Participants With Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT03034967

GlaxoSmithKlinePulmonary Disease, Chronic Obstructive

Start: 2017-04-25End: 2018-10-05Updated: 2020-10-28

Randomised, Double-Blind(Sponsor Open), Placebo-Controlled, Multicentre, Dose Ranging Study to Evaluate the Efficacy and Safety of Danirixin Tablets Administered Twice Daily Compared With Placebo for 24Weeks in Adult Participants With Chronic Obstructive Pulmonary Disease (COPD) (study 205724)

Active, not recruitingNL-OMON45435

GlaxoSmithKlinechronic obstructive airways disease (COPD)

Start: 2017-09-04Target: 50Updated: 2024-02-28

Randomized Study Evaluating the Effect of Danirixin on Neutrophil Extracellular Traps (NETs) in Chronic Obstructive Pulmonary Disease (COPD)

TerminatedNCT03250689

GlaxoSmithKlinePulmonary Disease, Chronic Obstructive

Start: 2017-11-15End: 2018-10-08Updated: 2021-03-29

Related Papers

CXCR2 antagonist for patients with chronic obstructive pulmonary disease with chronic mucus hypersecretion: a phase 2b trial

Respiratory Research2020-06-1267 citations

The COPD Pipeline XXXVII

Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation2018-01-01

Late Breaking Abstract - Danirixin (GSK1325756) improves respiratory symptoms and health status in mild to moderate COPD – results of a 1 year first time in patient study

2017-09-01

Assessing symptoms in COPD: Use of the E-RS daily digital diary in early drug development

2016-09-01